By Crystal Phend, Senior Staff Writer, MedPage Today
Another novel urine test appears to improve detection of prostate cancer, particularly of aggressive tumors, researchers reported.
The test, which measures a gene fusion product called TMPRSS2:ERG, or T2:ERG, predicted a positive biopsy significantly more accurately than did serum prostate specific antigen (PSA) alone or in combination with other clinical predictors, according to a study led by James B. Amberson, MD, of the laboratory company DIANON Systems in Shelton, Conn.
Continue Reading
No comments:
Post a Comment